Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study (Mol Cancer Ther. 2023 Oct 2;22(10):1191-1203.) By lsc-webmaster Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study (Mol Cancer Ther. 2023 Oct 2;22(10):1191-1203.) Read More »
Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade (Mol Cancer Ther. 2022 Sep 6;21(9):1462-1472.) By lsc-webmaster Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade (Mol Cancer Ther. 2022 Sep 6;21(9):1462-1472.) Read More »
PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers (Mol Cancer Ther. 2020 Oct;19(10):2068-2078.) By lsc-webmaster PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers (Mol Cancer Ther. 2020 Oct;19(10):2068-2078.) Read More »
